Abstract | OBJECTIVE: METHODS: FINDINGS: Of 191 enrolled patients, 6 and 8 were excluded or lost to follow-up before day 14 and between day 14 and day 28, respectively. For the AQ-treated patients, parasitological and clinical evaluation on day 14 showed late treatment failure in 2 of 61 (3.3%) and adequate clinical response with parasitological failure in one (1.6%). There was an adequate clinical response in all patients treated with SP or SP+AQ. Therapeutic failure rates on day 28 were 13.6%, 10.2% and 0% in the SP, AQ, and SP+AQ groups, respectively. Anaemia improved in all three regimens. AQ produced faster fever clearance but was associated with more transient minor side-effects than SP. SP+AQ reduced the risk of recrudescence between day 14 and day 28 but increased the incidence of minor side-effects. CONCLUSION: SP+AQ can be recommended as a temporary means of slowing the spread of multidrug resistance in Plasmodium falciparum in Africa while the introduction of other combinations, including artemisinin derivatives, is awaited.
|
Authors | Leonardo K Basco, Albert Same-Ekobo, Vincent Foumane Ngane, Mathieu Ndounga, Theresia Metoh, Pascal Ringwald, Georges Soula |
Journal | Bulletin of the World Health Organization
(Bull World Health Organ)
Vol. 80
Issue 7
Pg. 538-45
( 2002)
ISSN: 0042-9686 [Print] Switzerland |
PMID | 12163917
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antimalarials
- Drug Combinations
- Amodiaquine
- fanasil, pyrimethamine drug combination
- Sulfadoxine
- Pyrimethamine
|
Topics |
- Administration, Oral
- Amodiaquine
(therapeutic use)
- Antimalarials
(therapeutic use)
- Cameroon
(epidemiology)
- Child
- Child, Preschool
- Drug Administration Schedule
- Drug Combinations
- Drug Monitoring
- Drug Resistance
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- Hematocrit
- Humans
- Malaria, Falciparum
(blood, drug therapy, epidemiology, parasitology)
- Male
- Parasitic Sensitivity Tests
- Pyrimethamine
(therapeutic use)
- Sulfadoxine
(therapeutic use)
- Time Factors
- Treatment Outcome
|